News Review - NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) , J C Penney ... Techsonian (press release) ... Drugs Advisory Committee voted 8 to 5 that the available data support the approval of NatparaŽ (rhPTH [1-84]) for the long-term treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH.
Natpara Recommended by FDA Panel for Hyperparathyroidism Medscape Recombinant human parathyroid hormone (rhPTH[1-84]) (Natpara, NPS Pharmaceuticals) has been recommended for approval for the long-term treatment of hypoparathyroidism by a Food and Drug Administration (FDA) advisory committee. On September ...
Worldwide "Parathyroid" News Courtesy of Google